Organotropism of Metastatic Breast Cancer in Patients from Veracruz

Authors

Xavier Rodriguez-Bello
Alma Campos-Parra
Thuluz Meza-Menchaca
Manuel González del Carmen

Keywords:

Breast cancer, metastasis, organotropism, classification, Public Health

Abstract

Introduction: Organotropism refers to the tendency of malignant tumor cells to metastasize to specific distant organs. In breast cancer, organotropism may be influenced by molecular subtype. Objective: To describe the organotropism of distant metastases in patients from Veracruz with metastatic breast cancer (MBC). Materials and Methods: A retrospective, cross-sectional, observational study was conducted using medical records of MBC patients treated at two hospitals in Xalapa, Veracruz, between 2015 and 2023. Results and Discussion: A total of 269 clinical records were analyzed. The most frequent site of organotropism was bone (n=175, 42.6%), followed by lung (n=119, 29.0%). The contralateral breast was the least frequently affected site (n=7, 1.7%). Molecular subtype was significantly associated with metastasis site (p = 0.006). Patients with Luminal subtypes and bone metastases had better overall survival compared to those with visceral metastases (p< 0.001). Conclusions: In patients from Veracruz with MBC, bone is the most frequent site of organotropism. The Luminal A subtype appears to have a particular predilection for bone metastases. These patients also showed better overall survival.

References

Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Epidemiología del cáncer mamario en México. En: Décima revisión del consenso mexicano sobre diagnóstico y tratamiento del cáncer mamario [Internet]. Colima; 2023. p. 18–20. Disponible en: http://consensocancermamario.com/documentos/FOLLETO_CONSENSO_DE_-CANCER_DE_MAMA_10aRev2023a.PDF

Reynoso-Noverón N, Villarreal-Garza C, Soto-Perez-de-Celis E, Arce-Salinas C, Matus-Santos J, Ramírez-Ugalde MT, et al. Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular. J Glob Oncol. diciembre de 2017;3(6):757–64.

Gogate A, Wheeler SB, Reeder-Hayes KE, Ekwueme DU, Fairley TL, Drier S, et al. Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030. JNCI Cancer Spectrum. el 6 de julio de 2021;5(4):pkab063.

Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. febrero de 2024;35(2):159–82.

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). The Breast [Internet]. el 1 de agosto de 2024 [citado el 7 de octubre de 2025];76. Disponible en: https://doi.org/10.1016/j.breast.2024.103756

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. julio de 2024;22(5):331–57.

Grote I, Poppe A, Lehmann U, Christgen M, Kreipe H, Bartels S. Frequency of genetic alterations differs in advanced breast cancer between metastatic sites. Genes Chromosomes & Cancer. enero de 2024;63(1):e23199.

Cha S, Lee E, Won HH. Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites. npj Breast Cancer. el 16 de julio de 2021;7(1):93.

Savard MF, Khan O, Hunt KK, Verma S. Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer. Am Soc Clin Oncol Educ Book. el 17 de mayo de 2019;(39):e8–21.

Wei S, Siegal GP. Metastatic Organotropism: An Intrinsic Property of Breast Cancer Molecular Subtypes. Adv Anat Pathol. marzo de 2017;24(2):78–81.

Zhang M, Deng H, Hu R, Chen F, Dong S, Zhang S, et al. Patterns and prognostic implications of distant metastasis in breast Cancer based on SEER population data. Sci Rep. el 23 de julio de 2025;15(1):26717.

Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. enero de 2017;161(2):279–87.

Xie Y, Ma J, Xia X, Zheng H, Gou Q. Prognosis and Treatment of Metastatic Breast Cancer From A Real-World Scenario in China: A Retrospective Cohort Study. Cancer Control. noviembre de 2022;29:10732748221130568.

Jordan-Alejandre E, Campos-Parra AD, Castro-López DL, Silva-Cázares MB. Potential miRNA Use as a Biomarker: From Breast Cancer Diagnosis to Metastasis. Cells. Feb 6;12(4):525.

Ali Moradi A, Moradi M, Hosseini S, Garmsiri A, Bahari E, Bahrami F, et al. Organotropism of breast cancer metastasis: A comprehensive approach to the shared gene network. Gene Reports. el 1 de marzo de 2023;30:101749.

Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. npj Precision Onc. el 16 de febrero de 2018;2(1):4.

Cámara de Diputados del H. Congreso de la Unión. Reglamento de la Ley General de Salud en Materia de Investigación para la Salud [Internet]. 2014. Disponible en: https://www.diputados.gob.mx/LeyesBiblio/regley/Reg_LGS_MIS.pdf

Zhang Y, Sun C, Yau V, Chen S, Yang Q, Chen W, et al. Clinical Features and Prognosis of Uncommon Metastatic Breast Cancer: A Retrospective Analysis of 82 Cases. Technol Cancer Res Treat. enero de 2023;22:15330338231184990.

Kesireddy M, Masih D, Shostrom VK, Yellala A, Asif S, Krishnamurthy J. Overall Survival and Prognostic Factors in De Novo Metastatic Human Epidermal Growth Factor Receptor (HER)-2-Positive Breast Cancer: A National Cancer Database Analysis. Cancers. el 30 de mayo de 2025;17(11):1823.

Alvarado-Miranda A, Lara-Medina FU, Muñoz- Montaño WR, Zinser-Sierra JW, Galeana PAC, Garza CV, et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Current Oncology. el 24 de junio de 2023;30(7):6097–110.

Alhalabi A, Abdo T, Hijazi A, Mohanna M, Tfayli R, Herrán M, et al. Factors associated with developing and surviving brain metastases in patients with breast cancer: a multi-center experience. BMC Cancer. el 19 de diciembre de 2025;26(1):121.

Koyama Y, Horimoto Y, Yamada A, Narui K, Yamamoto S, Kaise H, et al. Organ-Specific Clinicopathological Features That Are Associated With Post-Relapse Survival of Metastatic Breast Cancer in Japanese Women: A Multicenter Cohort Study. World J Oncol. febrero de 2026;17(1):52–62.

Karthik J, Sehrawat A, Kapoor M, Sundriyal D. Navigating breast cancer brain metastasis: Risk factors, prognostic indicators, and treatment perspectives. World J Clin Oncol. el 24 de mayo de 2024;15(5):594–8.

Zhang W, Wu S, Liu J, Zhang X, Ma X, Yang C, et al. Metastasis patterns and prognosis in young breast cancer patients: A SEER database analysis. Front Oncol. el 13 de octubre de 2022;12:872862.

Liu K, Huang AL, Chen XQ, Wu SG. Patterns of distant metastasis and survival outcomes in de novo metastatic breast cancer according to age groups. Front Endocrinol. el 1 de mayo de 2024;15:1385756.

Arceo-Martínez MT, López-Meza JE, Ochoa-Zarzosa A, Palomera-Sanchez Z. Estado actual del cáncer de mama en México: principales tipos y factores de riesgo. GAMO. el 29 de julio de 2021;20(3):6748.

Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. diciembre de 2019;19(1):1091.